Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas.

Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, Mitterhauser M, Spindelegger C, Philippe C, Fink M, Wadsak W, Karanikas G, Kasper S.

Neuroimage. 2012 Nov 1;63(2):874-81. doi: 10.1016/j.neuroimage.2012.07.023. Epub 2012 Jul 22.

PMID:
22828162
2.

Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression.

Hahn A, Haeusler D, Kraus C, Höflich AS, Kranz GS, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R.

Hum Brain Mapp. 2014 Aug;35(8):3857-66. doi: 10.1002/hbm.22442. Epub 2014 Jan 17.

PMID:
24443158
3.

Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM.

Yeh YW, Ho PS, Kuo SC, Chen CY, Liang CS, Yen CH, Huang CC, Ma KH, Shiue CY, Huang WS, Shyu JF, Wan FJ, Lu RB, Huang SY.

Int J Neuropsychopharmacol. 2015 Jan 7;18(7):pyu120. doi: 10.1093/ijnp/pyu120.

4.

Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET.

Baldinger P, Kranz GS, Haeusler D, Savli M, Spies M, Philippe C, Hahn A, Höflich A, Wadsak W, Mitterhauser M, Lanzenberger R, Kasper S.

Neuroimage. 2014 Mar;88:252-62. doi: 10.1016/j.neuroimage.2013.10.002. Epub 2013 Oct 11.

PMID:
24121201
5.

Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.

Kim E, Howes OD, Park JW, Kim SN, Shin SA, Kim BH, Turkheimer FE, Lee YS, Kwon JS.

Psychol Med. 2016 Jan;46(2):357-66. doi: 10.1017/S0033291715001865. Epub 2015 Oct 1.

PMID:
26423910
6.

Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study.

Kim E, Howes OD, Kim BH, Chon MW, Seo S, Turkheimer FE, Lee JS, Lee YS, Kwon JS.

Clin Pharmacokinet. 2017 Apr;56(4):371-381. doi: 10.1007/s40262-016-0444-x.

PMID:
27557550
7.

Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression.

Smith GS, Kahn A, Sacher J, Rusjan P, van Eimeren T, Flint A, Wilson AA.

Am J Geriatr Psychiatry. 2011 Dec;19(12):1016-25. doi: 10.1097/JGP.0b013e318227f83f.

8.

Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM.

Herold N, Uebelhack K, Franke L, Amthauer H, Luedemann L, Bruhn H, Felix R, Uebelhack R, Plotkin M.

J Neural Transm (Vienna). 2006 May;113(5):659-70. Epub 2006 Feb 9.

PMID:
16465456
9.

In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, Pötzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S.

Psychopharmacology (Berl). 2006 Oct;188(3):263-72. Epub 2006 Sep 6.

PMID:
16955282
10.

Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.

Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB.

Biol Psychiatry. 2004 Oct 1;56(7):497-502.

PMID:
15450785
11.

Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.

Ruhé HG, Ooteman W, Booij J, Michel MC, Moeton M, Baas F, Schene AH.

Pharmacogenet Genomics. 2009 Jan;19(1):67-76. doi: 10.1097/FPC.0b013e32831a6a3a.

PMID:
18987562
12.

Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.

Lundberg J, Tiger M, Landén M, Halldin C, Farde L.

Int J Neuropsychopharmacol. 2012 Sep;15(8):1167-72. doi: 10.1017/S1461145711001945. Epub 2012 Jan 16.

13.

5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.

Stenkrona P, Halldin C, Lundberg J.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1190-8. doi: 10.1016/j.euroneuro.2013.01.002. Epub 2013 Feb 18.

PMID:
23428337
14.

Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.

Finnema SJ, Halldin C, Bang-Andersen B, Bundgaard C, Farde L.

Psychopharmacology (Berl). 2015 Nov;232(21-22):4159-67. doi: 10.1007/s00213-015-3961-7. Epub 2015 May 17.

PMID:
25980484
15.
16.

High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People.

Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R.

Biol Psychiatry. 2015 Oct 15;78(8):525-33. doi: 10.1016/j.biopsych.2014.09.010. Epub 2014 Sep 23.

17.

[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].

Mnie-Filali O, El Mansari M, Scarna H, Zimmer L, Sánchez C, Haddjeri N.

Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Review. French.

PMID:
18789789
18.

Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder.

Ruhé HG, Koster M, Booij J, van Herk M, Veltman DJ, Schene AH.

Psychiatry Res. 2014 Feb 28;221(2):155-61. doi: 10.1016/j.pscychresns.2013.12.003. Epub 2013 Dec 19.

PMID:
24406081
19.
20.

Supplemental Content

Support Center